

Special Issue

Diagnosis and Therapeutic Management of Gastrointestinal Cancers

Message from the Guest Editors

Gastrointestinal cancers are showing increasing incidence and mortality rates worldwide and are responsible for 4.8 million new cancer cases and 3.4 million cancer related deaths per year (WHO 2018). In addition to advances in combinations of conventional chemotherapy with targeted treatment options and upcoming immunotherapy, novel strategies in tumor treatment have yielded remarkable benefits for the patients. Translational and clinical research introduction of targeted immune and/or chemotherapy regimens as well as advancements in surgical technology (minimal invasive surgery, robotic surgery) have led to a significant reduction of morbidity and shown increasingly promising results in the recent past. Despite these new advancements, challenges still remain, including regarding issues of preventive measures (e.g., screening for chronic hepatitis, preventive endoscopies, etc.) as well as healthcare and/or reimbursement questions. This issue will cover the topics related to the diagnosis and therapeutic management of gastrointestinal cancers by presenting reviews and/or meta-analyses as well as recent results from original research.

Guest Editors

Prof. Dr. Christian Sebesta
Klinik Floridsdorf Wiener Gesundheitsverbund, Vienna, Austria
Prof. Dr. Harald Rosen
Faculty of Medicine, Sigmund Freud University, Vienna, Austria

Deadline for manuscript submissions

closed (15 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/127850

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)